Zacks Research Has Optimistic Outlook of HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.88 per share for the quarter, up from their prior estimate of $0.87. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.09 EPS, Q1 2026 earnings at $1.30 EPS, Q2 2026 earnings at $1.42 EPS, Q3 2026 earnings at $1.56 EPS, FY2026 earnings at $6.00 EPS and FY2027 earnings at $7.39 EPS.

A number of other equities research analysts also recently commented on the company. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark reiterated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $62.89.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $60.03 on Thursday. Halozyme Therapeutics has a 52 week low of $38.88 and a 52 week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The company has a market capitalization of $7.42 billion, a P/E ratio of 17.50, a P/E/G ratio of 0.42 and a beta of 1.32. The stock’s fifty day moving average is $60.73 and its two-hundred day moving average is $55.32.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,697 shares of company stock valued at $1,558,052 in the last three months. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 207 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $69,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.